SALT LAKE CITY, UT -- (MARKET WIRE) -- February 08, 2007 -- Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that it sold 3,000,000 shares of its common stock pursuant to an effective shelf registration statement. Myriad has also granted the underwriter a 30-day option to purchase an additional 450,000 shares of common stock to cover over-allotments, if any. The Company expects that the net proceeds from the public offering will be approximately $105 million, and approximately $120 million if the underwriter exercises its over-allotment option in full. All of the shares were sold by Myriad.
